124 related articles for article (PubMed ID: 1311219)
1. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data.
van der Gaast A; Sonneveld P; Mans DR; Splinter TA
Cancer Chemother Pharmacol; 1992; 29(4):335-7. PubMed ID: 1311219
[TBL] [Abstract][Full Text] [Related]
2. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.
Postmus PE; Holthuis JJ; Haaxma-Reiche H; Mulder NH; Vencken LM; van Oort WJ; Sleijfer DT; Sluiter HJ
J Clin Oncol; 1984 Mar; 2(3):215-20. PubMed ID: 6321690
[TBL] [Abstract][Full Text] [Related]
3. [A case of small cell lung cancer with renal insufficiency effectively treated with oral etoposide administration].
Akiyama Y; Kondo H; Kimura S; Fujii Y
Gan To Kagaku Ryoho; 1995 Apr; 22(5):683-6. PubMed ID: 7717722
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
[TBL] [Abstract][Full Text] [Related]
5. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.
Cunningham D; Cummings J; Blackie RB; McTaggart L; Banham SW; Kaye SB; Soukop M
Med Oncol Tumor Pharmacother; 1988; 5(2):117-23. PubMed ID: 2842552
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
[TBL] [Abstract][Full Text] [Related]
8. Higher in vivo protein binding of etoposide in children compared with adult cancer patients.
Liliemark E; Söderhäll S; Sirzea F; Gruber A; Osby E; Björkholm M; Zhou R; Peterson C; Liliemark J
Cancer Lett; 1996 Aug; 106(1):97-100. PubMed ID: 8827052
[TBL] [Abstract][Full Text] [Related]
9. Prolonged response of meningeal carcinomatosis from non-small cell lung cancer to salvage intrathecal etoposide subsequent to failure of first-line methotrexate: a case report and literature review.
Park MJ
Am J Case Rep; 2015 Apr; 16():224-7. PubMed ID: 25879815
[TBL] [Abstract][Full Text] [Related]
10. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration.
Kiya K; Uozumi T; Ogasawara H; Sugiyama K; Hotta T; Mikami T; Kurisu K
Cancer Chemother Pharmacol; 1992; 29(5):339-42. PubMed ID: 1312906
[TBL] [Abstract][Full Text] [Related]
11. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
Grunberg SM; Crowley J; Hande KR; Giroux D; Munshi N; Lau DH; Schroder LE; Zangmeister MH; Balcerzak SP; Hynes HE; Gandara DR
Cancer Chemother Pharmacol; 1999; 44(6):461-8. PubMed ID: 10550566
[TBL] [Abstract][Full Text] [Related]
12. High-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study.
Luikart SD; Propert KJ; Modeas CR; Green MR; Perry MC
Cancer Treat Rep; 1987 May; 71(5):533-4. PubMed ID: 3032434
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.
Joel SP; Ellis P; O'Byrne K; Papamichael D; Hall M; Penson R; Nicholls S; O'Donnell C; Constantinou A; Woodhull J; Nicholson M; Smith I; Talbot D; Slevin M
J Clin Oncol; 1996 Jun; 14(6):1903-12. PubMed ID: 8656259
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients.
Katoh O; Yamada H; Hiura K; Aoki Y; Kuroki S
J Clin Pharmacol; 1991 Dec; 31(12):1155-60. PubMed ID: 1662234
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
16. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE
Oncology; 1997; 54(5):363-70. PubMed ID: 9260596
[TBL] [Abstract][Full Text] [Related]
17. [Clinical trial of high-dose etoposide].
Yoshida T; Nakazumi Y; Kanno M; Kobayashi K; Ito K; Kondo K; Kanamori K; Nakamura S; Matsuda T
Gan To Kagaku Ryoho; 1988 Mar; 15(3):469-74. PubMed ID: 2831820
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients.
Chen CL; Rawwas J; Sorrell A; Eddy L; Uckun FM
Leuk Lymphoma; 2001 Jul; 42(3):317-27. PubMed ID: 11699396
[TBL] [Abstract][Full Text] [Related]
19. Low-dose oral etoposide: a new role for an old drug?
Slevin ML
J Clin Oncol; 1990 Oct; 8(10):1607-9. PubMed ID: 2170588
[No Abstract] [Full Text] [Related]
20. High-dose etoposide for central nervous system metastases of small cell lung cancer. Preliminary results.
Postmus PE; Haaxma-Reiche H; Sleijfer DT; Kleisbauer JP; ten Velde G; Kirkpatrick A
Eur J Respir Dis Suppl; 1987; 149():65-71. PubMed ID: 3034652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
